Palatin Technologies PT-141, known as bremelanotide or Vyleesi, is FDA-approved for premenopausal women with HSDD. Here's how it works, dosing, and safety.
PT-141 (bremelanotide) is a melanocortin receptor agonist developed by Palatin Technologies and approved by the FDA in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Unlike Viagra and Cialis, which increase blood flow to the genitals, PT-141 acts on the central nervous system and is designed to influence sexual desire itself. Palatin Technologies PT-141 is not approved for men or postmenopausal women, and the research-peptide versions sold online are not FDA-regulated.
What Is PT-141 and Who Developed It?
Palatin Technologies is a biopharmaceutical company based in Cranbury, New Jersey, that focuses on melanocortin-based therapeutics. Its best-known molecule is bremelanotide, a synthetic peptide analog of alpha-melanocyte-stimulating hormone that binds melanocortin receptors, primarily MC4R, in the brain.
The compound started as a follow-up to Melanotan II, a peptide originally studied for tanning. Investigators noticed that trial participants reported increased sexual desire, and Palatin redirected the program toward sexual dysfunction.
Vyleesi is the commercial form of PT-141: a single-use 1.75 mg subcutaneous autoinjector. Palatin licensed US commercialization rights to a partner, and the product has changed hands since approval.
- Company: Palatin Technologies (Cranbury, New Jersey)
- Molecule: Bremelanotide (PT-141)
- Brand name: Vyleesi
- Mechanism: Melanocortin receptor agonist (MC4R)
- FDA approval: June 2019, for premenopausal women with acquired, generalized HSDD
How PT-141 Works vs. Viagra and Cialis
PT-141 is a central-acting agent. It activates melanocortin-4 receptors in the hypothalamus and related brain regions tied to dopamine signaling and sexual motivation. PDE5 inhibitors such as sildenafil and tadalafil work peripherally by relaxing smooth muscle and increasing blood flow.
That distinction matters when vascular function is normal but desire is low. A PDE5 inhibitor can improve erections without changing interest in sex, while PT-141 targets the desire pathway. Nausea is common with PT-141 because the same receptors are involved in appetite and gut signaling.
| Feature | PT-141 (bremelanotide) | PDE5 inhibitors |
|---|---|---|
| Primary target | Brain melanocortin receptors (MC4R) | Vascular smooth muscle |
| Main effect | Sexual desire | Blood flow and erection quality |
| FDA-approved for | Premenopausal women with HSDD | Erectile dysfunction; pulmonary arterial hypertension |
| Route | Subcutaneous injection | Oral tablet |
| Common side effects | Nausea, flushing, headache | Headache, flushing, nasal congestion |
PT-141 Dosage: Approved and Off-Label
The FDA-approved pt-141 dosage is 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. No more than one dose should be used in 24 hours, and no more than eight doses per month.
There is no approved pt-141 dosage for women who have gone through menopause, because the indication covers premenopausal women only. Higher doses were studied in earlier trials, including a 10 mg intranasal formulation, but nausea and blood pressure effects rose with dose.
| Use setting | Reported dose | Route | Regulatory status |
|---|---|---|---|
| Premenopausal women with HSDD | 1.75 mg | Subcutaneous autoinjector | FDA-approved (Vyleesi) |
| Postmenopausal women | No established dose | Not applicable | Not approved |
| Men (off-label in studies) | 1.75 to 10 mg | Subcutaneous or intranasal | Not approved |
| Online research chemical | Unverified | Varies | Not approved for human use |
PT-141 for Men and Other Off-Label Uses
Interest in pt-141 for men traces back to early erectile dysfunction trials, where intranasal bremelanotide produced modest improvements in some participants. Palatin ultimately prioritized female sexual dysfunction, and no male indication was ever approved.
Off-label male use is discussed in forums and some clinics, often alongside a PDE5 inhibitor. Because dosing, safety, and drug interactions in men have not been established in large trials, medical supervision matters.
Earlier versions of PT-141 were delivered as a nasal spray, and compounded nasal formulations still circulate. A do-it-yourself spray is not something a clinician would recommend, since sterility, accurate measurement, and preservative-free handling are difficult to achieve outside a licensed compounding pharmacy.
How Long PT-141 Lasts
The answer to how long does pt-141 last is measured in hours, not days. Bremelanotide peaks in the blood about an hour after injection and has a half-life of roughly 2.7 hours, with most users reporting effects that fade within two to six hours.
Follow the storage directions that come with the specific product you are prescribed, since temperature control affects peptide stability. Do not use a product that has been stored outside its labeled conditions.
Where to Buy PT-141 and What the Law Says
Vyleesi is a prescription drug, so where to buy pt-141 legally means a licensed US pharmacy with a clinician's prescription. Bremelanotide is not available over the counter in the United States.
Many websites sell PT-141 as a research chemical labeled not for human consumption. Those products are not FDA-approved, may be under- or over-dosed, and carry no guarantee of purity or sterility.
Safety and Side Effects of PT-141
- Nausea — the most common side effect, reported by roughly 40% of trial participants
- Flushing and headache
- Injection site reactions — pain, redness, or bruising
- Vomiting — less common but dose-related
- Transient blood pressure changes — a short-lived rise in blood pressure and drop in heart rate
- Focal hyperpigmentation — darkened patches on skin, gums, or nails with repeated use
PT-141 is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. It should not be used more than once in 24 hours or more than eight times per month.
Anyone considering PT-141, approved or off-label, should review cardiovascular history, current medications, and pregnancy status with a healthcare professional. This article is informational and is not medical advice.
Bottom Line
Palatin Technologies PT-141 is a real, FDA-approved drug sold as Vyleesi, but only for premenopausal women with acquired, generalized HSDD. It works through the brain's melanocortin system rather than through blood flow, which is why it is discussed as a desire drug rather than an erection drug. Men and postmenopausal women have no approved indication, and unregulated research-grade vials are not a safe substitute for a prescription.
Frequently Asked Questions
Is PT-141 approved by the FDA?
Yes, but for one indication only. Bremelanotide was approved in June 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not approved for men, for postmenopausal women, or as an over-the-counter product, and PT-141 sold online as a research chemical is not FDA-approved for human use.
How is PT-141 different from Viagra?
Viagra and Cialis are PDE5 inhibitors that increase blood flow to the penis, while PT-141 acts on melanocortin receptors in the brain that influence sexual desire. PT-141 is given as a subcutaneous injection rather than an oral tablet. The two are sometimes used together off-label, but that combination has not been formally approved.
What are the most common PT-141 side effects?
Nausea is the most frequently reported side effect, affecting roughly 40% of participants in clinical trials. Flushing, headache, injection site reactions, and vomiting are also common. PT-141 can cause a short-term rise in blood pressure and is contraindicated in people with uncontrolled hypertension or cardiovascular disease.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.